Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

被引：0

作者：

Nicholls, Stephen ^{[1
]}

Nelson, Adam ^{[1
]}

Ditmarsch, Marc ^{[2
]}

Kastelein, John ^{[2
]}

Ballantyne, Christie ^{[3
]}

Ray, Kausik ^{[4
]}

Navar, Ann Marie ^{[5
]}

Nissen, Steven ^{[6
]}

Goldberg, Anne ^{[7
]}

Brunham, Liam ^{[8
]}

Wuerdeman, Erin ^{[9
]}

Neild, Annie ^{[10
]}

Kling, Douglas ^{[11
]}

Hsieh, Andrew ^{[12
]}

Ference, Brian ^{[13
]}

Laufs, Ulrich ^{[14
]}

Banach, Maciej ^{[15
]}

Mehran, Roxana ^{[16
]}

Catapano, Alberico ^{[17
]}

Davidson, Michael ^{[2
]}

机构：

[1] Victorian Heart Hosp, Clayton, Vic, Australia

[2] New Amsterdam Pharma, Amsterdam, Netherlands

[3] Baylor Coll Med, Houston, TX 77030 USA

[4] Imperial Coll London, London, England

[5] UT Southwestern Med Ctr, Dallas, TX USA

[6] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ British C0lumbia, Vancouver, BC, Canada

[9] NewAmsterdam Pharma, Cincinnati, OH USA

[10] NewAmsterdam Pharma, Aventura, FL USA

[11] NewAmsterdam Pharma, Lebanon, NJ USA

[12] Univ Illinois, Long Grove, IL USA

[13] Deep Causal AI, Cambridge, England

[14] Univ Clin Leipzig, Leipzig, Germany

[15] Med Univ Lodz, Lodz, Poland

[16] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[17] Univ Milan, Milan, Italy

来源：

CIRCULATION | 2024年 / 150卷 / 25期

关键词：

CETP inhibitors; Lipids; Clinical trials; Dyslipidemia; Prevention;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4171281

引用

页码：E729 / E730

页数：2

共 50 条

[1] Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
Reeskamp, Laurens F.
Kastelein, John J. P.
Moriarty, Patrick M.
Duell, P. Barton
Catapano, Alberico L.
Santos, Raul D.
Ballantyne, Christie M.
ATHEROSCLEROSIS, 2019, 280 : 109 - 117
[2] Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Henry N. Ginsberg
Jaakko Tuomilehto
G. Kees Hovingh
Bertrand Cariou
Raul D. Santos
Alan S. Brown
Santosh K. Sanganalmath
Andrew Koren
Desmond Thompson
Frederick J. Raal
Cardiovascular Drugs and Therapy, 2019, 33 : 69 - 76
[3] Impact of Age on the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia
Ginsberg, Henry N.
Tuomilehto, Jaakko
Hovingh, G. Kees
Cariou, Bertrand
Santos, Raul D.
Brown, Alan S.
Sanganalmath, Santosh K.
Koren, Andrew T.
Thompson, Desmond E.
Raal, Frederick J.
CIRCULATION, 2017, 136
[4] Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Ginsberg, Henry N.
Tuomilehto, Jaakko
Hovingh, G. Kees
Cariou, Bertrand
Santos, Raul D.
Brown, Alan S.
Sanganalmath, Santosh K.
Koren, Andrew
Thompson, Desmond
Raal, Frederick J.
CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (01) : 69 - 76
[5] THE EFFICACY AND SAFETY OF ALIROCUMAB IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: ODYSSEY KIDS
Daniels, Stephen R.
Caprio, Sonia
Chaudhari, Umesh
Manvelian, Garen
Baccara-Dinet, Marie
Brunet, Aurelie
Scemama, Michel
Loizeau, Virginie
Bruckert, Eric
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1860 - 1860
[6] Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia
Mabuchi, H
Koizumi, J
Kajinami, K
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (4B): : 52J - 55J
[7] Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia
Van der Graaf, A.
Nierman, M. C.
Firth, J. C.
Wolmarans, K. H.
Marais, A. D.
De Groot, E.
ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 585 - 585
[8] ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia
Ginsberg, Henry N.
Rader, Daniel J.
Raal, Frederick J.
Guyton, John R.
Lorenzato, Christelle
Pordy, Robert
Baccara-Dinet, Marie T.
Stroes, Eric S.
CIRCULATION, 2014, 130 (23) : 2119 - 2119
[9] Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
Hovingh, G. Kees
Raal, Frederick J.
Dent, Ricardo
Stefanutti, Claudia
Descamps, Olivier
Masana, Luis
Lira, Armando
Bridges, Ian
Coll, Blai
Sullivan, David
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (06) : 1448 - 1457
[10] Efficacy and safety of pravastatin 40 mg day in Japanese patients with heterozygous familial hypercholesterolemia
Mabuchi, H
Matsuzawa, Y
Saito, Y
Gunji, A
ATHEROSCLEROSIS, 1999, 144 : 194 - 194

← 1 2 3 4 5 →